$ANAB
AnaptysBio Inc Stock $anab

$anab Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000137005322000066 Filed on November 08, 2022

Income Statement

Concept	2022 Q4	2022 Q3
Revenue	$6.808M	$1.293M
YoY Change	573.39%	-93.81%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$9.407M	$8.862M
YoY Change	74.46%	63.14%
% of Gross Profit
Research & Development	$23.37M	$22.06M
YoY Change	-12.71%	-0.71%
% of Gross Profit
Depreciation & Amortization	$184.0K	$166.0K
YoY Change	11.52%	-1.78%
% of Gross Profit
Operating Expenses	$32.78M	$30.93M
YoY Change	1.91%	11.84%
Operating Profit		-$29.63M
YoY Change		338.16%
Interest Expense	$3.839M	$2.262M
YoY Change	5545.59%	3434.38%
% of Operating Profit
Other Income/Expense, Net	-$4.255M	-$3.869M
YoY Change	193.65%	-4088.66%
Pretax Income	-$26.39M	-$33.50M
YoY Change	-18.9%	402.58%
Income Tax	$24.00K
% Of Pretax Income
Net Earnings	-$26.41M	-$33.50M
YoY Change	-18.82%	402.58%
Net Earnings / Revenue	-387.97%	-2591.03%
Basic Earnings Per Share		-$1.18
Diluted Earnings Per Share	-$0.93	-$1.18
COMMON SHARES
Basic Shares Outstanding	28.43M shares	28.24M shares
Diluted Shares Outstanding		28.29M shares

Balance Sheet

Concept	2022 Q4	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$441.2M	$443.0M
YoY Change	-19.5%	18.42%
Cash & Equivalents	$71.31M	$58.55M
Short-Term Investments	$369.9M	$384.4M
Other Short-Term Assets	$4.545M	$6.298M
YoY Change	-7.3%	-46.71%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$447.2M	$450.4M
YoY Change	-19.26%	16.5%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.089M	$1.972M
YoY Change	-8.5%	-18.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$142.9M	$147.5M
YoY Change	113.03%	867.79%
Other Assets	$256.0K	$256.0K
YoY Change	0.0%	-0.78%
Total Long-Term Assets	$163.2M	$168.1M
YoY Change	82.95%	345.89%
TOTAL ASSETS
Total Short-Term Assets	$447.2M	$450.4M
Total Long-Term Assets	$163.2M	$168.1M
Total Assets	$610.4M	$618.5M
YoY Change	-5.08%	45.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.784M	$3.006M
YoY Change	59.91%	-47.42%
Accrued Expenses	$21.63M	$16.45M
YoY Change	68.31%	16.9%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$26.05M	$21.06M
YoY Change	61.84%	0.83%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$322.2M	$319.8M
YoY Change	19.1%	1512.16%
Total Long-Term Liabilities	$322.2M	$319.8M
YoY Change	19.1%	1512.16%
TOTAL LIABILITIES
Total Short-Term Liabilities	$26.05M	$21.06M
Total Long-Term Liabilities	$322.2M	$319.8M
Total Liabilities	$348.3M	$340.9M
YoY Change	21.5%	737.0%
SHAREHOLDERS EQUITY
Retained Earnings	-$450.5M	-$424.1M
YoY Change	40.01%	46.63%
Common Stock	$29.00K	$28.00K
YoY Change	3.57%	3.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$262.1M	$277.6M
YoY Change
Total Liabilities & Shareholders Equity	$610.4M	$618.5M
YoY Change	-5.08%	45.76%

Cashflow Statement

Concept	2022 Q4	2022 Q3
OPERATING ACTIVITIES
Net Income	-$26.41M	-$33.50M
YoY Change	-18.82%	402.58%
Depreciation, Depletion And Amortization	$184.0K	$166.0K
YoY Change	11.52%	-1.78%
Cash From Operating Activities	-$10.69M	-$17.75M
YoY Change	-57.77%	153.31%
INVESTING ACTIVITIES
Capital Expenditures	$175.0K	-$50.00K
YoY Change	-1350.0%	-70.93%
Acquisitions
YoY Change
Other Investing Activities	$21.67M	-$32.38M
YoY Change	-132.5%	-394.11%
Cash From Investing Activities	$21.50M	-$32.43M
YoY Change	-132.23%	-399.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.949M	37.03M
YoY Change	-99.22%	15263.9%
NET CHANGE
Cash From Operating Activities	-10.69M	-17.75M
Cash From Investing Activities	21.50M	-32.43M
Cash From Financing Activities	1.949M	37.03M
Net Change In Cash	12.76M	-13.15M
YoY Change	-91.99%	-422.88%
FREE CASH FLOW
Cash From Operating Activities	-$10.69M	-$17.75M
Capital Expenditures	$175.0K	-$50.00K
Free Cash Flow	-$10.86M	-$17.70M
YoY Change	-57.05%	158.96%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001370053
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-37985
	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://www.anaptysbio.com/20220930#CollaborationRevenueMember
	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://www.anaptysbio.com/20220930#CollaborationRevenueMember
CY2021Q3	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://www.anaptysbio.com/20220930#CollaborationRevenueMember
CY2022Q3	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://www.anaptysbio.com/20220930#CollaborationRevenueMember
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Entity Registrant Name EntityRegistrantName	ANAPTYSBIO, INC
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-3828755
	dei	Entity Address Address Line1 EntityAddressAddressLine1	10770 Wateridge Circle
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 210
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
	dei	City Area Code CityAreaCode	858
	dei	Local Phone Number LocalPhoneNumber	362-6295
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	ANAB
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	28431632	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	58547000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	495729000	usd
CY2022Q3	us-gaap	Receivables Net Current ReceivablesNetCurrent	1180000	usd
CY2021Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	876000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	384419000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	52368000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6298000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4903000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	450444000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	553876000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1972000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2283000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	18320000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19558000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	147511000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	67097000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	256000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	256000	usd
CY2022Q3	us-gaap	Assets Assets	618503000	usd
CY2021Q4	us-gaap	Assets Assets	643070000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3006000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1741000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16453000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12853000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1604000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1505000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	21063000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16099000	usd
CY2022Q3	anab	Advance Future Royalties Liability Noncurrent AdvanceFutureRoyaltiesLiabilityNoncurrent	301586000	usd
CY2021Q4	anab	Advance Future Royalties Liability Noncurrent AdvanceFutureRoyaltiesLiabilityNoncurrent	251093000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	18235000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	19450000	usd
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28354000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28354000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27647000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27647000	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	28000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	28000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	707662000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	678575000	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6007000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-422000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-424064000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-321753000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	277619000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	356428000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	618503000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	643070000	usd
CY2022Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1293000	usd
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20890000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3479000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	62164000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22064000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22221000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	65424000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	71720000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8862000	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5432000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	27236000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16101000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	30926000	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	27653000	usd
	us-gaap	Operating Expenses OperatingExpenses	92660000	usd
	us-gaap	Operating Expenses OperatingExpenses	87821000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-29633000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6763000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-89181000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-25657000	usd
CY2022Q3	us-gaap	Interest Income Other InterestIncomeOther	2262000	usd
CY2021Q3	us-gaap	Interest Income Other InterestIncomeOther	64000	usd
	us-gaap	Interest Income Other InterestIncomeOther	3711000	usd
	us-gaap	Interest Income Other InterestIncomeOther	363000	usd
CY2022Q3	anab	Noncash Advance Future Royalties Interest Expense NoncashAdvanceFutureRoyaltiesInterestExpense	6135000	usd
CY2021Q3	anab	Noncash Advance Future Royalties Interest Expense NoncashAdvanceFutureRoyaltiesInterestExpense	0	usd
	anab	Noncash Advance Future Royalties Interest Expense NoncashAdvanceFutureRoyaltiesInterestExpense	16857000	usd
	anab	Noncash Advance Future Royalties Interest Expense NoncashAdvanceFutureRoyaltiesInterestExpense	0	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4000	usd
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	33000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	16000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	36000	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3869000	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	97000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-13130000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	399000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-33502000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-6666000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-102311000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25258000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-2146000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-24000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-5585000	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-196000	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35648000	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6690000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-107896000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-25454000	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.18
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.18
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.24
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.64
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.64
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.92
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.92
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28289000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28289000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27436000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27436000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28071000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28071000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27397000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27397000	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	356428000	usd
CY2022Q1	anab	Stock Issued During Period Value Options And Employee Stock Purchase Plan StockIssuedDuringPeriodValueOptionsAndEmployeeStockPurchasePlan	4844000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	7742000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2012000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-36255000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	330747000	usd
CY2022Q2	anab	Stock Issued During Period Value Options And Employee Stock Purchase Plan StockIssuedDuringPeriodValueOptionsAndEmployeeStockPurchasePlan	882000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	6658000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-1427000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-32554000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	304306000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2690000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	6271000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2146000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-33502000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	277619000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	396731000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	167000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	3315000	usd
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-107000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-18163000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	381943000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	592000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	3690000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-65000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-429000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	385731000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	203000	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	4364000	usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-24000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-6666000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	383608000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-102311000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-25258000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	491000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	454000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	20671000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	11369000	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	784000	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-393000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1238000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1251000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-16857000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	15000	usd
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	304000	usd
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	761000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2518000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	8541000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4868000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	581000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1116000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-92000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-62908000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20619000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	674925000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	26482000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	258766000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	133348000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	15000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	183000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1352000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-416342000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	105529000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8408000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	962000	usd
	anab	Proceeds From Sale Of Advance Future Royalties ProceedsFromSaleOfAdvanceFutureRoyalties	35000000	usd
	anab	Proceeds From Sale Of Advance Future Royalties ProceedsFromSaleOfAdvanceFutureRoyalties	0	usd
	anab	Advance Future Royalty And Milestone Payments AdvanceFutureRoyaltyAndMilestonePayments	1050000	usd
	anab	Advance Future Royalty And Milestone Payments AdvanceFutureRoyaltyAndMilestonePayments	0	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	290000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	42068000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	962000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-437182000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	85872000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	495729000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	250516000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58547000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	336388000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	28000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	11000	usd
	anab	Noncash Advance Future Royalties Issuance Costs Incurred But Not Yet Paid NoncashAdvanceFutureRoyaltiesIssuanceCostsIncurredButNotYetPaid	24000	usd
	anab	Noncash Advance Future Royalties Issuance Costs Incurred But Not Yet Paid NoncashAdvanceFutureRoyaltiesIssuanceCostsIncurredButNotYetPaid	0	usd
	anab	Receivables For Stock Options Exercised ReceivablesForStockOptionsExercised	8000	usd
	anab	Receivables For Stock Options Exercised ReceivablesForStockOptionsExercised	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	20685000	usd
	us-gaap	Nature Of Operations NatureOfOperations	Description of the Business<div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AnaptysBio, Inc. (“we,” “us,” “our,” or the “Company”) was incorporated in the state of Delaware in November 2005. We are a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics. We are developing immune cell modulators, including two checkpoint agonists in clinical-stage development, for autoimmune and inflammatory disease: rosnilimab, our anti-PD-1 agonist program, previously referred to as ANB030, which is currently in a Phase 2 clinical trial for the treatment of moderate-to-severe alopecia areata; and ANB032, our anti-BTLA agonist program. In addition, we are developing imsidolimab, our anti-IL-36R antibody, which is currently in a Phase 3 clinical trial for the treatment of generalized pustular psoriasis, or GPP. We also have additional preclinical programs and discovery research of potentially innovative immunology therapeutics, including ANB033, an anti-CD122 antagonist antibody for the treatment of inflammatory diseases. We have also developed multiple therapeutic antibodies in an immuno-oncology collaboration with GSK, including an anti-PD-1 antagonist antibody (JEMPERLI (dostarlimab-gxly)), an anti-TIM-3 antagonist antibody (cobolimab, GSK4069889) and an anti-LAG-3 antagonist antibody (GSK4074386). We currently generate revenue from milestones and royalties achieved under our immuno-oncology collaboration with GSK. Our antibody pipeline has been developed using our proprietary somatic hypermutation, or SHM platform, which uses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SHM for antibody discovery and is designed to replicate key features of the human immune system to overcome the limitations of competing antibody discovery technologies.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have devoted our primary effort to research and development activities. Our financial support has been provided primarily from the sale of our common stock, royalty monetizations, as well as through funds received under our collaborative research and development agreements. Going forward, as we continue our expansion, we may seek additional financing and/or strategic investments. However, there can be no assurance that any additional financing or strategic investments will be available to us on acceptable terms, if at all. If events or circumstances occur such that we do not obtain additional funding, we will most likely be required to reduce our plans and/or certain discretionary spending, which could have a material adverse effect on our ability to achieve our intended business objectives. Our management believes our currently available resources will provide sufficient funds to enable us to meet our operating plans for at least the next twelve months from the issuance of our consolidated financial statements. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.</span></div>
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying consolidated financial statements in conformity with U.S. GAAP requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and reported amounts of revenues and expenses during </span></div>the reporting periods. Actual results could differ from those estimates. We base our estimates and assumptions on historical experience when available and on various factors that we believe to be reasonable under the circumstances. We evaluate our estimates and assumptions on an ongoing basis. The full extent to which the COVID-19 pandemic will directly or indirectly impact our business, results of operations, and financial condition, including expenses, reserves and allowances, manufacturing, clinical trials, research and development costs, and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, as well as the economic impact on local, regional, national and international markets. Our actual results could differ from these estimates under different assumptions or conditions.
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7384000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7205000	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5412000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4922000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1972000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2283000	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3904000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4177000	usd
CY2022Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1000000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	569000	usd
CY2022Q3	anab	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	11412000	usd
CY2021Q4	anab	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	7953000	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	137000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	154000	usd
CY2022Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	16453000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	12853000	usd
	us-gaap	Contract With Customer Timing Of Satisfaction Of Performance Obligation And Payment ContractWithCustomerTimingOfSatisfactionOfPerformanceObligationAndPayment	Milestones achieved during the discovery period were recognized as revenue pro-rata through December 31, 2016. Milestones achieved during fiscal 2017 were recognized as revenue in the period earned, while milestones after December 31, 2017 are recognized upon determination that a significant reversal of revenue would not be probable. Cash is generally received within 30 days of milestone achievement.
CY2022Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	537730000	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000	usd
CY2022Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	5805000	usd
CY2022Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	531930000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	119680000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	217000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	119465000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	497530000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	5716000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	4387000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	89000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	501917000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	5805000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months	108694000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	217000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	108694000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	217000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	5800000	usd
CY2021Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss	200000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	100000	usd
CY2022Q3	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28354167	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28354167	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3711635	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1030443	shares
CY2022Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8656031	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3460295	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	28.84
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M1D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	42987000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1339720	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	29.44
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	685970	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	11.72
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	402410	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	31.26
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3711635	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	31.96
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y2M26D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	10248000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1761210	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	36.71
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y5M4D
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	6713000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6271000	usd
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4364000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20671000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11369000	usd
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.040
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y10M24D
	us-gaap	Operating Lease Cost OperatingLeaseCost	1858000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1594000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1732000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	516000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2531000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2607000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	585000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2386000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2457000	usd
CY2022Q3	anab	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	13239000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	23805000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3966000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	19839000	usd
CY2021Q4	anab	Sale Of Stock Maximum Aggregate Offering SaleOfStockMaximumAggregateOffering	150000000	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001370053-22-000066-index-headers.html	Edgar Link	pending
0001370053-22-000066-index.html	Edgar Link	pending
0001370053-22-000066.txt	Edgar Link	pending
0001370053-22-000066-xbrl.zip	Edgar Link	pending
anab-20220930.htm	Edgar Link	pending
anab-20220930.xsd	Edgar Link	pending
anab-20220930_g1.jpg	Edgar Link	pending
anab-20220930_def.xml	Edgar Link	unprocessable
anab-20220930_lab.xml	Edgar Link	unprocessable
anab-20220930_pre.xml	Edgar Link	unprocessable
anab-20220930_htm.xml	Edgar Link	completed
anab-51opinion2022sx3_at.htm	Edgar Link	pending
anab-51opinion2022sx3_at001.jpg	Edgar Link	pending
anab-51opinion2022sx3_at002.jpg	Edgar Link	pending
anab-51opinion2022sx3_at003.jpg	Edgar Link	pending
anab-51opinion2022sx3_at004.jpg	Edgar Link	pending
anab-9302022x10qxexx311.htm	Edgar Link	pending
anab-9302022x10qxexx312.htm	Edgar Link	pending
anab-9302022x10qxexx321.htm	Edgar Link	pending
anab-9302022x10qxexx322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
salesagreementex1024_fin.htm	Edgar Link	pending
salesagreementex1024_fin001.jpg	Edgar Link	pending
salesagreementex1024_fin002.jpg	Edgar Link	pending
salesagreementex1024_fin003.jpg	Edgar Link	pending
salesagreementex1024_fin004.jpg	Edgar Link	pending
salesagreementex1024_fin005.jpg	Edgar Link	pending
salesagreementex1024_fin006.jpg	Edgar Link	pending
salesagreementex1024_fin007.jpg	Edgar Link	pending
salesagreementex1024_fin008.jpg	Edgar Link	pending
salesagreementex1024_fin009.jpg	Edgar Link	pending
salesagreementex1024_fin010.jpg	Edgar Link	pending
salesagreementex1024_fin011.jpg	Edgar Link	pending
salesagreementex1024_fin012.jpg	Edgar Link	pending
salesagreementex1024_fin013.jpg	Edgar Link	pending
salesagreementex1024_fin014.jpg	Edgar Link	pending
salesagreementex1024_fin015.jpg	Edgar Link	pending
salesagreementex1024_fin016.jpg	Edgar Link	pending
salesagreementex1024_fin017.jpg	Edgar Link	pending
salesagreementex1024_fin018.jpg	Edgar Link	pending
salesagreementex1024_fin019.jpg	Edgar Link	pending
salesagreementex1024_fin020.jpg	Edgar Link	pending
salesagreementex1024_fin021.jpg	Edgar Link	pending
salesagreementex1024_fin022.jpg	Edgar Link	pending
salesagreementex1024_fin023.jpg	Edgar Link	pending
salesagreementex1024_fin024.jpg	Edgar Link	pending
salesagreementex1024_fin025.jpg	Edgar Link	pending
salesagreementex1024_fin026.jpg	Edgar Link	pending
salesagreementex1024_fin027.jpg	Edgar Link	pending
salesagreementex1024_fin028.jpg	Edgar Link	pending
salesagreementex1024_fin029.jpg	Edgar Link	pending
salesagreementex1024_fin030.jpg	Edgar Link	pending
salesagreementex1024_fin031.jpg	Edgar Link	pending
salesagreementex1024_fin032.jpg	Edgar Link	pending
salesagreementex1024_fin033.jpg	Edgar Link	pending
salesagreementex1024_fin034.jpg	Edgar Link	pending
salesagreementex1024_fin035.jpg	Edgar Link	pending
salesagreementex1024_fin036.jpg	Edgar Link	pending
salesagreementex1024_fin037.jpg	Edgar Link	pending
salesagreementex1024_fin038.jpg	Edgar Link	pending
salesagreementex1024_fin039.jpg	Edgar Link	pending
salesagreementex1024_fin040.jpg	Edgar Link	pending
Show.js	Edgar Link	pending
zejularoyaltypurchaseagr.htm	Edgar Link	pending
zejularoyaltypurchaseagr001.jpg	Edgar Link	pending
zejularoyaltypurchaseagr002.jpg	Edgar Link	pending
zejularoyaltypurchaseagr003.jpg	Edgar Link	pending
zejularoyaltypurchaseagr004.jpg	Edgar Link	pending
zejularoyaltypurchaseagr005.jpg	Edgar Link	pending
zejularoyaltypurchaseagr006.jpg	Edgar Link	pending
zejularoyaltypurchaseagr007.jpg	Edgar Link	pending
zejularoyaltypurchaseagr008.jpg	Edgar Link	pending
zejularoyaltypurchaseagr009.jpg	Edgar Link	pending
zejularoyaltypurchaseagr010.jpg	Edgar Link	pending
zejularoyaltypurchaseagr011.jpg	Edgar Link	pending
zejularoyaltypurchaseagr012.jpg	Edgar Link	pending
zejularoyaltypurchaseagr013.jpg	Edgar Link	pending
zejularoyaltypurchaseagr014.jpg	Edgar Link	pending
zejularoyaltypurchaseagr015.jpg	Edgar Link	pending
zejularoyaltypurchaseagr016.jpg	Edgar Link	pending
zejularoyaltypurchaseagr017.jpg	Edgar Link	pending
zejularoyaltypurchaseagr018.jpg	Edgar Link	pending
zejularoyaltypurchaseagr019.jpg	Edgar Link	pending
zejularoyaltypurchaseagr020.jpg	Edgar Link	pending
zejularoyaltypurchaseagr021.jpg	Edgar Link	pending
zejularoyaltypurchaseagr022.jpg	Edgar Link	pending
zejularoyaltypurchaseagr023.jpg	Edgar Link	pending
zejularoyaltypurchaseagr024.jpg	Edgar Link	pending
zejularoyaltypurchaseagr025.jpg	Edgar Link	pending
zejularoyaltypurchaseagr026.jpg	Edgar Link	pending
zejularoyaltypurchaseagr027.jpg	Edgar Link	pending
zejularoyaltypurchaseagr028.jpg	Edgar Link	pending
zejularoyaltypurchaseagr029.jpg	Edgar Link	pending
zejularoyaltypurchaseagr030.jpg	Edgar Link	pending
zejularoyaltypurchaseagr031.jpg	Edgar Link	pending
zejularoyaltypurchaseagr032.jpg	Edgar Link	pending
zejularoyaltypurchaseagr033.jpg	Edgar Link	pending
zejularoyaltypurchaseagr034.jpg	Edgar Link	pending
zejularoyaltypurchaseagr035.jpg	Edgar Link	pending
zejularoyaltypurchaseagr036.jpg	Edgar Link	pending
zejularoyaltypurchaseagr037.jpg	Edgar Link	pending
anab-20220930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ANAB
AnaptysBio Inc Stock $anab

2022 Q4 Form 10-Q Financial Statement

#000137005322000066 Filed on November 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANAB AnaptysBio Inc Stock $anab

2022 Q4 Form 10-Q Financial Statement

#000137005322000066 Filed on November 08, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANAB
AnaptysBio Inc Stock $anab